We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Face Reconstruction by Allotransplantation of Composite Tissues

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00527280
Recruitment Status : Completed
First Posted : September 10, 2007
Last Update Posted : March 22, 2017
Sponsor:
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
To show the feasibility of face transplantation in patients

Condition or disease Intervention/treatment Phase
Reconstruction of the Face Procedure: Feasibility ot face transplantation Phase 2

Detailed Description:
Most facial defects can be reconstructed with autologous tissues using standard plastic surgical techniques. However, when the circular facial muscles (eg. orbicularis oculi and orbicularis oris) are destroyed by burns, ballistic traumas, tumors, or congenital deformities there are no conventional surgical solutions. The study was designed following the advice of the French National Ethics Advisory Committee for life sciences and health (CCNE). The objectives are to study the feasibility and efficacy of face CTA transplantation, functional results, and influence on quality-of-life, as well as the management of immunosuppression.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Face Reconstruction by Allotransplantation of Composite Tissues
Study Start Date : January 2007
Primary Completion Date : May 2016
Study Completion Date : May 2016

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: 1 Procedure: Feasibility ot face transplantation
Feasibility ot face transplantation



Primary Outcome Measures :
  1. Reconstruction tissular at carrier patients of a loss of substance of the median third(third party) of the face having taken the totality of lips with or without the nasal pyramid; or of a loss of substance taking the totality of 4 eyelids. [ Time Frame: during the study ]

Secondary Outcome Measures :
  1. To evaluate the potential benefit of such a transplantation in term of quality of life [ Time Frame: during the study ]
  2. To measure the impact of this improvement [ Time Frame: during the study ]
  3. To measure the impact of a immunosuppressive treatment for a pathology which is not vital [ Time Frame: during the study ]
  4. To evaluate Acute Graft rejection using skin and mucosa biopsies: function of the lips and or eyelids mobility and function of the orbicularis muscles Quality of life the psychiatric and psychological evaluations [ Time Frame: at in the following days weeks and month after surgery ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 18 through 65 years
  • Signed written informed consent
  • patient with a loss of substance of the median third of the face by traumatisms or not carrying the totality of the lips with or without the nasal pyramid.
  • validation of the feasibility by a committee of expert in plastic surgery and maxillofacial
  • patient with a positive psychologic evaluation
  • patient with an anatomical evaluation and assessment pretransplantation positive normal infectious assessment
  • Good compliance and capacity of adaptation to the assessment difficulties
  • Patient with renal, hepatic, hematologic ,cardiac normal
  • Patient profiting from a Social Security cover
  • Patient informed patient, having signed a free assent lit with inclusion in the study

Exclusion Criteria:

  • patient minor under supervision or deprived of freedom by court order or administrative.
  • person remaining in a medical or social establishment
  • pregnant. or breast-feeding women
  • patient presenting a sever cardiac pathology having a risk of decompensation into pre, per and post operational
  • patient presenting a hepatic pathology
  • Any cancer that has been in complete remission for > 5 years malignancies tumoral lesion of the face with 2 years deadline of remission respected renal insufficiency chronic clearance of creatin < 60l ml/mn
  • chronic respiratory insufficiency
  • patient presenting an active infection which can be worsened by the immunosuppression
  • patient presenting an active infection which can be worsened by the corticoid
  • patient with affection being able to compromise post-operative survival
  • patient with digestive ulcer
  • No known HIV infection
  • serology hepatitis B with circulating DNA highlighted quantitatively
  • personality emotional unstable
  • schizophrenic or not schizophrenic psychosis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00527280


Locations
France
Hopital européen Geroges Pompidou
Paris, France, 75015
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Investigators
Principal Investigator: Laurent LANTIERI, MD PhD Assistance Publique - Hôpitaux de Paris

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT00527280     History of Changes
Other Study ID Numbers: P050303
First Posted: September 10, 2007    Key Record Dates
Last Update Posted: March 22, 2017
Last Verified: March 2017

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Allotransplantation:composite tissue
Face transplantation